Expressions of 10 genes as candidate predictors of recurrence in stage III colon cancer patients receiving adjuvant oxaliplatin-based chemotherapy
Approximately 30% patients with stage III colon cancer (CC) develop local recurrence and/or distant metastasis, even if postoperative adjuvant chemotherapy with oxaliplatin plus 5-fluorouracil and leucovorin (5-FU/LV) has been completed. In the present study, molecular analysis was performed to iden...
Gespeichert in:
| Veröffentlicht in: | Oncology letters 2019-08, Vol.18 (2), p.1388-1394 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1394 |
|---|---|
| container_issue | 2 |
| container_start_page | 1388 |
| container_title | Oncology letters |
| container_volume | 18 |
| creator | Kumamoto, Kensuke Nakachi, Yutaka Mizuno, Yosuke Yokoyama, Masaru Ishibashi, Keiichiro Kosugi, Chihiro Koda, Keiji Kobayashi, Michiya Tanakaya, Kohji Matsunami, Toshio Eguchi, Hidetaka Okazaki, Yasushi Ishida, Hideyuki |
| description | Approximately 30% patients with stage III colon cancer (CC) develop local recurrence and/or distant metastasis, even if postoperative adjuvant chemotherapy with oxaliplatin plus 5-fluorouracil and leucovorin (5-FU/LV) has been completed. In the present study, molecular analysis was performed to identify molecular markers of tumor recurrence in patients with stage III CC receiving oxaliplatin-based adjuvant chemotherapy. The FACOS study was conducted as a phase II study to evaluate the safety and efficacy of oxaliplatin-based treatment for stage III CC patients. Of the 132 CC patients enrolled in the present study, gene expression analysis using a microarray was conducted in 51 patients. Of these 51 patients, 6 developed recurrence within 5 years. The topmost 5% genes that showed differential expressions between cases that developed/did not develop recurrence were selected, and a set of predictive molecular markers for recurrence was identified. Of the 34,694 genes in the microarray, 1,734 genes were extracted as topmost 5% genes showing differential expressions between cases with and without recurrence. Among these, 10 genes, including
and
, were identified as markers that could clearly divide patients with and without recurrence. Although several prediction models of tumor recurrence have been reported for CC, the set of 10 genes that the present study identified may be useful to predict the risk of recurrence in stage III CC patients receiving oxaliplatin-based adjuvant chemotherapy. Based on these results, high-risk patients with CC should be carefully observed to detect tumor recurrence during the follow-up period. |
| doi_str_mv | 10.3892/ol.2019.10437 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6607086</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A594664942</galeid><sourcerecordid>A594664942</sourcerecordid><originalsourceid>FETCH-LOGICAL-c513t-469ad24996620273289a5e2af82b033c303e94bc187313ebd5a90f5c13807f933</originalsourceid><addsrcrecordid>eNptkl1vFCEUhidGY5u1l94aEhPjzax8zAfcmDRN1U2aeKPXhGXO7LBhYARm0_6N_mKZtq5dI1xA4DkvnHPeonhL8JpxQT95u6aYiDXBFWtfFOekFbQkmNOXx31bnRUXMe5xHnVDOG9eF2eMVJRRTM-L--vbKUCMxruIfI8IRjtwEJGKSCvXmU4lQBnpjE4-PDAB9BwCOA3IOBST2gHabDZIe-vdEqUhoEklAy7FhQZzMG6HVLefD8ol5G-VNZPNhCu3KkKH9ACjTwMENd29KV71yka4eFpXxc8v1z-uvpU3379uri5vSl0TlsqqEaqjlRBNkzNpGeVC1UBVz-kWM6YZZiCqrSa8ZYTBtquVwH2tCeO47QVjq-Lzo-40b0fodP5tUFZOwYwq3EmvjDy9cWaQO3-QTYNbzJss8PFJIPhfM8QkRxM1WKsc-DlKSttaVLyiOKPv_0H3fg4up5epuiY1r3H7l9opC9K43ud39SIqL7NS01Qi921VrP9D5dnBaLR30Jt8fhLw4VnAAMqmIXo7p6Xpp2D5COrgYwzQH4tBsFwMJ72Vi-Hkg-Ey_-55BY_0H3ux35Vt0D8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2255158507</pqid></control><display><type>article</type><title>Expressions of 10 genes as candidate predictors of recurrence in stage III colon cancer patients receiving adjuvant oxaliplatin-based chemotherapy</title><source>Spandidos Publications Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Kumamoto, Kensuke ; Nakachi, Yutaka ; Mizuno, Yosuke ; Yokoyama, Masaru ; Ishibashi, Keiichiro ; Kosugi, Chihiro ; Koda, Keiji ; Kobayashi, Michiya ; Tanakaya, Kohji ; Matsunami, Toshio ; Eguchi, Hidetaka ; Okazaki, Yasushi ; Ishida, Hideyuki</creator><creatorcontrib>Kumamoto, Kensuke ; Nakachi, Yutaka ; Mizuno, Yosuke ; Yokoyama, Masaru ; Ishibashi, Keiichiro ; Kosugi, Chihiro ; Koda, Keiji ; Kobayashi, Michiya ; Tanakaya, Kohji ; Matsunami, Toshio ; Eguchi, Hidetaka ; Okazaki, Yasushi ; Ishida, Hideyuki</creatorcontrib><description>Approximately 30% patients with stage III colon cancer (CC) develop local recurrence and/or distant metastasis, even if postoperative adjuvant chemotherapy with oxaliplatin plus 5-fluorouracil and leucovorin (5-FU/LV) has been completed. In the present study, molecular analysis was performed to identify molecular markers of tumor recurrence in patients with stage III CC receiving oxaliplatin-based adjuvant chemotherapy. The FACOS study was conducted as a phase II study to evaluate the safety and efficacy of oxaliplatin-based treatment for stage III CC patients. Of the 132 CC patients enrolled in the present study, gene expression analysis using a microarray was conducted in 51 patients. Of these 51 patients, 6 developed recurrence within 5 years. The topmost 5% genes that showed differential expressions between cases that developed/did not develop recurrence were selected, and a set of predictive molecular markers for recurrence was identified. Of the 34,694 genes in the microarray, 1,734 genes were extracted as topmost 5% genes showing differential expressions between cases with and without recurrence. Among these, 10 genes, including
and
, were identified as markers that could clearly divide patients with and without recurrence. Although several prediction models of tumor recurrence have been reported for CC, the set of 10 genes that the present study identified may be useful to predict the risk of recurrence in stage III CC patients receiving oxaliplatin-based adjuvant chemotherapy. Based on these results, high-risk patients with CC should be carefully observed to detect tumor recurrence during the follow-up period.</description><identifier>ISSN: 1792-1074</identifier><identifier>EISSN: 1792-1082</identifier><identifier>DOI: 10.3892/ol.2019.10437</identifier><identifier>PMID: 31423202</identifier><language>eng</language><publisher>Greece: Spandidos Publications</publisher><subject>Adjuvant chemotherapy ; Alcohol ; Analysis ; Antineoplastic agents ; Biochemistry ; Biotechnology industries ; Cancer genetics ; Cancer metastasis ; Cancer patients ; Cancer therapies ; Cancer treatment ; Care and treatment ; Chemotherapy ; Colon cancer ; Colorectal cancer ; Dehydrogenases ; Development and progression ; Fluorouracil ; Folinic acid ; Gene expression ; Genes ; Lymphatic system ; Medical prognosis ; Medical research ; Mutation ; Oncology ; Patients ; Recurrence (Disease) ; Studies ; Tumors</subject><ispartof>Oncology letters, 2019-08, Vol.18 (2), p.1388-1394</ispartof><rights>COPYRIGHT 2019 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2019</rights><rights>Copyright: © Kumamoto et al. 2019</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c513t-469ad24996620273289a5e2af82b033c303e94bc187313ebd5a90f5c13807f933</citedby><cites>FETCH-LOGICAL-c513t-469ad24996620273289a5e2af82b033c303e94bc187313ebd5a90f5c13807f933</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607086/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607086/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31423202$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kumamoto, Kensuke</creatorcontrib><creatorcontrib>Nakachi, Yutaka</creatorcontrib><creatorcontrib>Mizuno, Yosuke</creatorcontrib><creatorcontrib>Yokoyama, Masaru</creatorcontrib><creatorcontrib>Ishibashi, Keiichiro</creatorcontrib><creatorcontrib>Kosugi, Chihiro</creatorcontrib><creatorcontrib>Koda, Keiji</creatorcontrib><creatorcontrib>Kobayashi, Michiya</creatorcontrib><creatorcontrib>Tanakaya, Kohji</creatorcontrib><creatorcontrib>Matsunami, Toshio</creatorcontrib><creatorcontrib>Eguchi, Hidetaka</creatorcontrib><creatorcontrib>Okazaki, Yasushi</creatorcontrib><creatorcontrib>Ishida, Hideyuki</creatorcontrib><title>Expressions of 10 genes as candidate predictors of recurrence in stage III colon cancer patients receiving adjuvant oxaliplatin-based chemotherapy</title><title>Oncology letters</title><addtitle>Oncol Lett</addtitle><description>Approximately 30% patients with stage III colon cancer (CC) develop local recurrence and/or distant metastasis, even if postoperative adjuvant chemotherapy with oxaliplatin plus 5-fluorouracil and leucovorin (5-FU/LV) has been completed. In the present study, molecular analysis was performed to identify molecular markers of tumor recurrence in patients with stage III CC receiving oxaliplatin-based adjuvant chemotherapy. The FACOS study was conducted as a phase II study to evaluate the safety and efficacy of oxaliplatin-based treatment for stage III CC patients. Of the 132 CC patients enrolled in the present study, gene expression analysis using a microarray was conducted in 51 patients. Of these 51 patients, 6 developed recurrence within 5 years. The topmost 5% genes that showed differential expressions between cases that developed/did not develop recurrence were selected, and a set of predictive molecular markers for recurrence was identified. Of the 34,694 genes in the microarray, 1,734 genes were extracted as topmost 5% genes showing differential expressions between cases with and without recurrence. Among these, 10 genes, including
and
, were identified as markers that could clearly divide patients with and without recurrence. Although several prediction models of tumor recurrence have been reported for CC, the set of 10 genes that the present study identified may be useful to predict the risk of recurrence in stage III CC patients receiving oxaliplatin-based adjuvant chemotherapy. Based on these results, high-risk patients with CC should be carefully observed to detect tumor recurrence during the follow-up period.</description><subject>Adjuvant chemotherapy</subject><subject>Alcohol</subject><subject>Analysis</subject><subject>Antineoplastic agents</subject><subject>Biochemistry</subject><subject>Biotechnology industries</subject><subject>Cancer genetics</subject><subject>Cancer metastasis</subject><subject>Cancer patients</subject><subject>Cancer therapies</subject><subject>Cancer treatment</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Colon cancer</subject><subject>Colorectal cancer</subject><subject>Dehydrogenases</subject><subject>Development and progression</subject><subject>Fluorouracil</subject><subject>Folinic acid</subject><subject>Gene expression</subject><subject>Genes</subject><subject>Lymphatic system</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Mutation</subject><subject>Oncology</subject><subject>Patients</subject><subject>Recurrence (Disease)</subject><subject>Studies</subject><subject>Tumors</subject><issn>1792-1074</issn><issn>1792-1082</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNptkl1vFCEUhidGY5u1l94aEhPjzax8zAfcmDRN1U2aeKPXhGXO7LBhYARm0_6N_mKZtq5dI1xA4DkvnHPeonhL8JpxQT95u6aYiDXBFWtfFOekFbQkmNOXx31bnRUXMe5xHnVDOG9eF2eMVJRRTM-L--vbKUCMxruIfI8IRjtwEJGKSCvXmU4lQBnpjE4-PDAB9BwCOA3IOBST2gHabDZIe-vdEqUhoEklAy7FhQZzMG6HVLefD8ol5G-VNZPNhCu3KkKH9ACjTwMENd29KV71yka4eFpXxc8v1z-uvpU3379uri5vSl0TlsqqEaqjlRBNkzNpGeVC1UBVz-kWM6YZZiCqrSa8ZYTBtquVwH2tCeO47QVjq-Lzo-40b0fodP5tUFZOwYwq3EmvjDy9cWaQO3-QTYNbzJss8PFJIPhfM8QkRxM1WKsc-DlKSttaVLyiOKPv_0H3fg4up5epuiY1r3H7l9opC9K43ud39SIqL7NS01Qi921VrP9D5dnBaLR30Jt8fhLw4VnAAMqmIXo7p6Xpp2D5COrgYwzQH4tBsFwMJ72Vi-Hkg-Ey_-55BY_0H3ux35Vt0D8</recordid><startdate>20190801</startdate><enddate>20190801</enddate><creator>Kumamoto, Kensuke</creator><creator>Nakachi, Yutaka</creator><creator>Mizuno, Yosuke</creator><creator>Yokoyama, Masaru</creator><creator>Ishibashi, Keiichiro</creator><creator>Kosugi, Chihiro</creator><creator>Koda, Keiji</creator><creator>Kobayashi, Michiya</creator><creator>Tanakaya, Kohji</creator><creator>Matsunami, Toshio</creator><creator>Eguchi, Hidetaka</creator><creator>Okazaki, Yasushi</creator><creator>Ishida, Hideyuki</creator><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><general>D.A. Spandidos</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20190801</creationdate><title>Expressions of 10 genes as candidate predictors of recurrence in stage III colon cancer patients receiving adjuvant oxaliplatin-based chemotherapy</title><author>Kumamoto, Kensuke ; Nakachi, Yutaka ; Mizuno, Yosuke ; Yokoyama, Masaru ; Ishibashi, Keiichiro ; Kosugi, Chihiro ; Koda, Keiji ; Kobayashi, Michiya ; Tanakaya, Kohji ; Matsunami, Toshio ; Eguchi, Hidetaka ; Okazaki, Yasushi ; Ishida, Hideyuki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c513t-469ad24996620273289a5e2af82b033c303e94bc187313ebd5a90f5c13807f933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adjuvant chemotherapy</topic><topic>Alcohol</topic><topic>Analysis</topic><topic>Antineoplastic agents</topic><topic>Biochemistry</topic><topic>Biotechnology industries</topic><topic>Cancer genetics</topic><topic>Cancer metastasis</topic><topic>Cancer patients</topic><topic>Cancer therapies</topic><topic>Cancer treatment</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Colon cancer</topic><topic>Colorectal cancer</topic><topic>Dehydrogenases</topic><topic>Development and progression</topic><topic>Fluorouracil</topic><topic>Folinic acid</topic><topic>Gene expression</topic><topic>Genes</topic><topic>Lymphatic system</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Mutation</topic><topic>Oncology</topic><topic>Patients</topic><topic>Recurrence (Disease)</topic><topic>Studies</topic><topic>Tumors</topic><toplevel>online_resources</toplevel><creatorcontrib>Kumamoto, Kensuke</creatorcontrib><creatorcontrib>Nakachi, Yutaka</creatorcontrib><creatorcontrib>Mizuno, Yosuke</creatorcontrib><creatorcontrib>Yokoyama, Masaru</creatorcontrib><creatorcontrib>Ishibashi, Keiichiro</creatorcontrib><creatorcontrib>Kosugi, Chihiro</creatorcontrib><creatorcontrib>Koda, Keiji</creatorcontrib><creatorcontrib>Kobayashi, Michiya</creatorcontrib><creatorcontrib>Tanakaya, Kohji</creatorcontrib><creatorcontrib>Matsunami, Toshio</creatorcontrib><creatorcontrib>Eguchi, Hidetaka</creatorcontrib><creatorcontrib>Okazaki, Yasushi</creatorcontrib><creatorcontrib>Ishida, Hideyuki</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncology letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kumamoto, Kensuke</au><au>Nakachi, Yutaka</au><au>Mizuno, Yosuke</au><au>Yokoyama, Masaru</au><au>Ishibashi, Keiichiro</au><au>Kosugi, Chihiro</au><au>Koda, Keiji</au><au>Kobayashi, Michiya</au><au>Tanakaya, Kohji</au><au>Matsunami, Toshio</au><au>Eguchi, Hidetaka</au><au>Okazaki, Yasushi</au><au>Ishida, Hideyuki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Expressions of 10 genes as candidate predictors of recurrence in stage III colon cancer patients receiving adjuvant oxaliplatin-based chemotherapy</atitle><jtitle>Oncology letters</jtitle><addtitle>Oncol Lett</addtitle><date>2019-08-01</date><risdate>2019</risdate><volume>18</volume><issue>2</issue><spage>1388</spage><epage>1394</epage><pages>1388-1394</pages><issn>1792-1074</issn><eissn>1792-1082</eissn><abstract>Approximately 30% patients with stage III colon cancer (CC) develop local recurrence and/or distant metastasis, even if postoperative adjuvant chemotherapy with oxaliplatin plus 5-fluorouracil and leucovorin (5-FU/LV) has been completed. In the present study, molecular analysis was performed to identify molecular markers of tumor recurrence in patients with stage III CC receiving oxaliplatin-based adjuvant chemotherapy. The FACOS study was conducted as a phase II study to evaluate the safety and efficacy of oxaliplatin-based treatment for stage III CC patients. Of the 132 CC patients enrolled in the present study, gene expression analysis using a microarray was conducted in 51 patients. Of these 51 patients, 6 developed recurrence within 5 years. The topmost 5% genes that showed differential expressions between cases that developed/did not develop recurrence were selected, and a set of predictive molecular markers for recurrence was identified. Of the 34,694 genes in the microarray, 1,734 genes were extracted as topmost 5% genes showing differential expressions between cases with and without recurrence. Among these, 10 genes, including
and
, were identified as markers that could clearly divide patients with and without recurrence. Although several prediction models of tumor recurrence have been reported for CC, the set of 10 genes that the present study identified may be useful to predict the risk of recurrence in stage III CC patients receiving oxaliplatin-based adjuvant chemotherapy. Based on these results, high-risk patients with CC should be carefully observed to detect tumor recurrence during the follow-up period.</abstract><cop>Greece</cop><pub>Spandidos Publications</pub><pmid>31423202</pmid><doi>10.3892/ol.2019.10437</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1792-1074 |
| ispartof | Oncology letters, 2019-08, Vol.18 (2), p.1388-1394 |
| issn | 1792-1074 1792-1082 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6607086 |
| source | Spandidos Publications Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Adjuvant chemotherapy Alcohol Analysis Antineoplastic agents Biochemistry Biotechnology industries Cancer genetics Cancer metastasis Cancer patients Cancer therapies Cancer treatment Care and treatment Chemotherapy Colon cancer Colorectal cancer Dehydrogenases Development and progression Fluorouracil Folinic acid Gene expression Genes Lymphatic system Medical prognosis Medical research Mutation Oncology Patients Recurrence (Disease) Studies Tumors |
| title | Expressions of 10 genes as candidate predictors of recurrence in stage III colon cancer patients receiving adjuvant oxaliplatin-based chemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T17%3A41%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Expressions%20of%2010%20genes%20as%20candidate%20predictors%20of%20recurrence%20in%20stage%20III%20colon%20cancer%20patients%20receiving%20adjuvant%20oxaliplatin-based%20chemotherapy&rft.jtitle=Oncology%20letters&rft.au=Kumamoto,%20Kensuke&rft.date=2019-08-01&rft.volume=18&rft.issue=2&rft.spage=1388&rft.epage=1394&rft.pages=1388-1394&rft.issn=1792-1074&rft.eissn=1792-1082&rft_id=info:doi/10.3892/ol.2019.10437&rft_dat=%3Cgale_pubme%3EA594664942%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2255158507&rft_id=info:pmid/31423202&rft_galeid=A594664942&rfr_iscdi=true |